Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report No Results Phase 3 results in SAM-002
Leader sits at 66% across 5 bound outcomes, runner-up at 18%. This is a winner-take-all market — the headline is the leader’s price, not an arithmetic mean.
Leader probability
No Results
Outcomes
5
winner-take-all
Runner-up
18¢
Success
Spread
48pp
contested
24h volume
$86
thin orderbook
Closes
Jul 1, 2026
5 days
Venue
Kalshi
5 bound
30-day trend
Bracket family
How the bracket ladder is priced.
Each row is one outcome on the venue. Sorted by 24h volume — the heaviest book is at the top.
Cluster 1
Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report
Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report Mixed Phase 3 results in SAM-002?: Mixed
KXSAMSON-26-SAM-002-MIX
Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report Success Phase 3 results in SAM-002?: Success
KXSAMSON-26-SAM-002-SUC
Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report No Results Phase 3 results in SAM-002?: No Results
KXSAMSON-26-SAM-002-NR
Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report Ambiguous Phase 3 results in SAM-002?: Ambiguous
KXSAMSON-26-SAM-002-AMB
Will Samson Clinical Operations's male Androgenetic Alopecia (AGA) drug (Sublingual Minoxidil) report Failure Phase 3 results in SAM-002?: Failure
KXSAMSON-26-SAM-002-FAIL
Analysis
This market reflects a 65% probability that Samson Clinical Operations' sublingual minoxidil treatment for male hair loss will report inconclusive or unsuccessful Phase 3 results in the SAM-002 trial. The high probability of negative or ambiguous outcomes suggests market participants assign meaningful risk to the drug failing to demonstrate efficacy sufficient for regulatory approval. Current market pricing is driven by baseline skepticism about sublingual minoxidil as a novel delivery mechanism for a known compound, though limited recent clinical data appears publicly available. The resolution hinges on when Samson reports Phase 3 trial results, which would definitively establish whether the formulation met its primary efficacy endpoints. This matters because positive results would represent a new treatment option for androgenetic alopecia, while negative results would redirect the company's development priorities.
- ›Sublingual minoxidil is a reformulation of an existing compound; market may be pricing in difficulty demonstrating meaningful advantage over established topical delivery
- ›Phase 3 trial design specifics (primary endpoints, patient population, comparator choice) would significantly influence outcome probability if disclosed
- ›Absence of publicly available interim data or recent company updates may reflect either deliberate information control or lack of compelling preliminary signals
- ›Timeline to results announcement remains undefined; extended timelines without updates typically correlate with lower success probability in biotech markets
- ›Competitor landscape and regulatory precedent for other novel hair-loss formulations could shift probability if new approvals or failures occur
What moved the line
- Jun 18Mixed↑4pp2→6¢ · Kalshi
- Jun 19Failure↓4pp6→2¢ · Kalshi
- Jun 24Success↑3pp18→21¢ · Kalshi
Recently closed in oil
- Will Crude Oil (CL) hit__ by end of June?: ↓ $60last 88% · 7d
- What will the average monthly Ethereum gas price hit before 2027?: 5 Gweilast 47% · 7d
- Will Venezuelan crude oil production reach __ barrels per day in 2026?: 1.5mlast 96% · 7d
- What will Crude Oil (CL) settle at in June?: $77-$84last 35% · 7d
- Crude Oil (CL) above ___ end of June?: $65last 96% · 7d
These markets stopped trading. Last odds and any captured outcome are shown above — full settlement detail lives at the venue.
More like this
Other questions in oil.
In oil
Related reading
Bearish Oil Bets Surge as Iran Optimism Grows
The probability of crude oil (WTI) falling below $75 by end of June has skyrocketed 47 points to 89¢, with a 37% chance of hitting below $70. This is a direct response to the increased optimism around an Iran nuclear deal, which could bring significant Iranian oil supply back to the market.
Oil Traders Pivot to Bearish as Geopolitical Risk Premium Erodes
As the US-Iran peace deal narrative strengthens, oil markets are repricing lower. The probability of crude oil falling below $80 by end of June surged 17¢ to 81¢, while expectations for a rally above $120 collapsed. The VIX fell 4.41%, confirming a broader 'risk-on' shift that typically accompanies a reduction in geopolitical tensions.
How we compute these odds
SimpleFunctions aggregates live prediction-market contracts from Kalshi and Polymarket. Each slug groups contracts that resolve on the same underlying event, identified by venue event_id.
For binary slugs, the headline probability is the liquidity-weighted mid-price across all bound contracts. For multi-outcome slugs (e.g. elections with 3+ candidates), the headline is the leader’s price; we never arithmetically average disjoint outcomes — that would produce a number with no real-world meaning.
Snapshots refresh every 5 minutes during market hours; daily aggregates are computed at 04:00 UTC. The 30-day sparkline is drawn from per-ticker daily means stored in market_indicator_daily; 24h delta and movement events are derived from the same source.
Last updated on this page: just now.